The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.

@article{Xie2019TheEA,
  title={The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.},
  author={Wenting Xie and Han Zhang and ShanShan Qin and Jia-Jia Zhang and Xin Fan and Yu-Zhen Yin and Ruipeng Liang and Huideng Long and Wanwan Yi and Da Fu and Chao Ma and Mingli Lv and Fei Yu},
  journal={Gene},
  year={2019},
  pages={
          144088
        }
}
2 Citations
Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3
TLDR
A recombinant adenovirus expressing EGFR-targeting artificial microRNA and active revCASP3 (Ad-EC), under the control of tumor-specific SLPI promoter, is constructed and its inhibitory effect on HEP-2 cancer cells both in vitro and in vivo is evaluated.

References

SHOWING 1-10 OF 38 REFERENCES
Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer.
TLDR
Like hK7, ALP is down-regulated in prostate cancers, which begs the question of whether it remains an effective inhibitor of hK8 or whether it is discordant in time or space and is ineffective as an inhibitor ofhK7.
Secretory leukocyte peptidase inhibitor and lung cancer
TLDR
The normal function of SLPI is discussed and its possible roles in cancer tissues are discussed, including that of protecting proepithelin from elastase cleavage in wound healing.
Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer
TLDR
It is demonstrated that SLPI expression has functional significance, as it promotes CRPC cell survival and growth after androgen withdrawal in vivo and in vitro, and the oncogenic effect of SLPI may be due to protection of growth factor progranulin from enzymatic cleavage or suppression ofCRPC cell apoptosis independent of anti-protease activity ofSLPI.
Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells
TLDR
A two-pronged approach confirmed that SLPI overcomes paclitaxel in part through activation of ERK1/2 and credential SLPI as a molecular target for ovarian cancer and suggest CR012 as a tool for proof of concept.
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.
TLDR
Identification of genes associated with metastasis in experimental models may have clinical implications for the management of breast cancer, because some of these are associated with lymph node metastasis and survival and might be useful as prognostic markers or molecular targets for novel therapies.
The role of IL17B-IL17RB signaling pathway in breast cancer.
Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer
TLDR
The results indicate that SERPINE2 and SLPI play a significant role in the development of papillary thyroid cancer and imply that the evaluation of serum concentrations of both anticoagulant molecules may be considered as additional marker for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors.
Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes*
TLDR
The results suggest that SLPI acts at the node(s) of at least three major interacting growth inhibitory pathways, which may define a novel pathway by which cellular growth is modulated.
...
...